Cargando…

Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression

Claudin-18.2 (CLDN18.2) is specifically expressed in pancreatic precancerous lesions and pancreatic ductal adenocarcinoma (PDAC). We assessed the clinical characteristics of patients with CLDN18.2-overexpressing pancreatic cancer to identify patients who might benefit from CLDN18-targeted treatment....

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Sejun, Shin, Kabsoo, Kim, In-Ho, Hong, Taeho, Kim, Younghoon, Suh, Jahee, Lee, Myungah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455540/ https://www.ncbi.nlm.nih.gov/pubmed/37629433 http://dx.doi.org/10.3390/jcm12165394

Ejemplares similares

Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
por: Kim, Hyung-Don, et al.
Publicado: (2023)

Histologic subtype-based evaluation of recurrence and survival outcomes in patients with adenocarcinoma of the ampulla of Vater
por: Park, Se Jun, et al.
Publicado: (2023)

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer
por: Park, Se Jun, et al.
Publicado: (2023)

Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma
por: Jamiyan, Tsengelmaa, et al.
Publicado: (2020)

Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma
por: Vay, Christian, et al.
Publicado: (2022)

Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma
por: Ji, Meiying, et al.
Publicado: (2017)

Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody
por: Torres, Julia Baguña, et al.
Publicado: (2017)

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
por: Lohneis, Philipp, et al.
Publicado: (2018)

The effects of CYP24A1 on clinicopathological features and the prognosis of pancreatic ductal adenocarcinoma
por: Gao, Wei, et al.
Publicado: (2020)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
por: Klempner, S.J., et al.
Publicado: (2023)

Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
por: Zhang, Yalu, et al.
Publicado: (2021)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma
por: Zhang, Luan-Jing, et al.
Publicado: (2014)

A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2019)

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Park, Se Jun, et al.
Publicado: (2021)

RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients
por: Pereira, Marina Alessandra, et al.
Publicado: (2021)

Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma
por: Matsushita, Katsunori, et al.
Publicado: (2021)

Claudin‐1 correlates with poor prognosis in lung adenocarcinoma
por: Sun, Bing‐sheng, et al.
Publicado: (2016)

Coexpression of EGFR and CXCR4 Predicts Poor Prognosis in Resected Pancreatic Ductal Adenocarcinoma
por: Wu, Huanwen, et al.
Publicado: (2015)

Overexpression of rhophilin 2 promotes pancreatic ductal adenocarcinoma
por: Bo, Wentao, et al.
Publicado: (2021)

Prognostic Significance of Claudin 4 in Completely Resected Adenocarcinoma of the Lung
por: Chae, Min Cheol, et al.
Publicado: (2014)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
por: Arnold, A., et al.
Publicado: (2020)

Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Kim, Dong Wook, et al.
Publicado: (2022)

The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast
por: Jin, Haidan, et al.
Publicado: (2016)

Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis
por: Ungureanu, Bogdan Silviu, et al.
Publicado: (2021)

COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis
por: Pomianowska, Ewa, et al.
Publicado: (2014)

Targeting claudin‐4 enhances chemosensitivity of pancreatic ductal carcinomas
por: Sasaki, Takamitsu, et al.
Publicado: (2019)

Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis
por: MacCurtain, Benjamin M., et al.
Publicado: (2021)

Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma
por: Leppänen, Joni, et al.
Publicado: (2018)

Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma
por: Li, Xiaojie, et al.
Publicado: (2020)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection
por: Flis, Vojko, et al.
Publicado: (2016)

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
por: Lekka, Kyriaki, et al.
Publicado: (2019)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Bonds, Morgan, et al.
Publicado: (2019)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

Early recurrence detected by (18)F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma
por: Wang, Li, et al.
Publicado: (2020)

Role of adjuvant chemotherapy on recurrence and survival in patients with resected ampulla of Vater carcinoma
por: Park, Se Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_roaqpd05quvt57khb1kp356dd8